	Nutritional Risk Assessed by Royal Free Hospital-Nutritional Prioritizing Tool Predicts Survival in Cirrhosis With or Without Hepatocellular Carcinoma. J Korean Med Sci Park HJ, Jung JK, Noh J, Kim Y, Lee SU, Yun BC, Lee JW, Kim HJ, Seo KI. PMID: 42089136 [PubMed - indexed for MEDLINE]
	Multi-omics insights into tumor grade progression in clear cell renal cell carcinoma: from molecular mechanisms to precision therapeutics. Front Cell Dev Biol Jena RS, Mishra A. PMID: 42089114 [PubMed]
	Fructose metabolism as an adaptive survival axis in pancreatic cancer: mechanistic insights and therapeutic implications. Front Med (Lausanne) Zhang Y, Zhang Y. PMID: 42089053 [PubMed]
	Retracted: Evaluation of morphology and angiogenesis of breast cancer in BALB/c mice using trypsin inhibitor from Cucumis melo seeds. In vitro and in vivo study. Contemp Oncol (Pozn) Rezaei S, Azarpira N, Koohpeyma F, Yousefi R, Doaei S, Heidari M, Gholamalizadeh M, Haghshenas MR, Mazloom Z. PMID: 42089040 [PubMed]
	Combined analysis of metabolomics and transcriptomics reveals new indicators for the diagnosis and prognosis of colorectal cancer. Contemp Oncol (Pozn) Guo M, Jin B. PMID: 42089037 [PubMed]
	In silico approach and in vitro study of fangchinoline-induced apoptosis and reactive oxygen species production in HER2-overexpressing breast cancer cells. Contemp Oncol (Pozn) Satria D, Hasibuan PAZ, Masfria M, Waruwu SB, Yeun-Mun C, Hermanto FE, Widodo N. PMID: 42089032 [PubMed]
	Esophagogastric Variceal Bleeding in Cirrhotic Patients with Hepatocellular Carcinoma Receiving Systemic Therapy: A Retrospective Cohort Study. J Hepatocell Carcinoma Li Y, Zeng A, Li Y, Wang Y, Yu Y, Lyu L, Han Y, Ding H. PMID: 42088985 [PubMed]
	Immunomodulatory mediators IL-33, soluble ST2, IL-10, IFN-Î³ in the serum of patients with oral potentially malignant disorders and oral squamous cell carcinoma. Front Oral Health Acharya S, Hegde U, Madhunapantula SRV, Karnik M, Acharya AB, Shetty P. PMID: 42088894 [PubMed]
	Presence of glyphosate in endometrial cancer tissue: A cross-sectional study. Toxicol Rep Unicsovics M, Szentirmay A, Fekécs G, Plank P, Molnár Z, Nagyéri G, Posta K, Ács N, Várbíró S, Sára L, Sz. PMID: 42088831 [PubMed]
	Outcomes of pelvic radiotherapy with boost strategies in high nodal-risk prostate cancer: A phase 2 prospective trial. Clin Transl Radiat Oncol Thellenberg Karlsson C, Notstam K, Tavelin B, Lundqvist K, Fransson P, Söderkvist K. PMID: 42088776 [PubMed]
	Predicting Prostate Cancer Risk and Its Associated Factors Using Machine Learning Techniques: A Retrospective Study. Health Sci Rep Mohammadi S, Imani B, Saeedi S, Amirzargar MA. PMID: 42088668 [PubMed]
	Diagnostic Delays in Thoracic Cancer Care: A Data-Linkage, Cohort Study between Primary Care, Hospital, and Registry Data. Health Data Sci Zhang J, IJzerman MJ, McCarthy D, Bergin RJ, Kearney C, Philip S, Lee A, Wang X, Solomon B, Alexander M, Wright GM, Emery JD. PMID: 42088654 [PubMed]
	The Brazilian Genome Map Oncology Subproject: a nationwide multicentre hospital-based whole-genome sequencing study of breast, prostate, and colorectal cancer. Lancet Reg Health Am Ferreira FO, Rossi BM, Palmero EI, Carvalho Barros LR, Domingos de Nicola P, Monteiro Dos Santos EM, Pereira de Souza J, Thiago de Souza-Santos P, Matta BP, da Silva Sabato C, Braz NC, Monteleone VF, Campacci N, Bastos GM, Guerra TS, Quirino CV, Pereira N, de Oliveira Costa M, Alves da Silva A, Serra AL, Lopes AJ, Alves Coelho BL, Mylla de Aguiar D, Chagas GL, Silva da Costa J, Lima JF, Jaqueline de Souza M, Oliveira SR, da Fonseca C, Cascapera F, Alencar de Moura FA, Perroni Dos Santos G, Guimaraes da Silva L, Campacci L, Sacilotto L, Soares Dos Santos S, Queiroz WDS, Goto GT, Badesso Fonseca TR, De Oliveira Mattoschoell VY, Rosa RO, Sandoval RL, Gambardella DD, Ciconelli RM, Beraldo da Costa Saad M, Guimaraes GC, Collaborative Working Group . PMID: 42088596 [PubMed]
	Favorable safety outcomes of a perioperative propranolol and etodolac regimen in cancer patients in four randomized controlled trials. Front Pharmacol Sakis N, Sorski L, Asraf E, Ricon-Becker I, Shaashua L, Haldar R, Shvalbo BB, Shabat-Simon M, Gutman M, Nissan A, Nachmany I, Kent I, Pery R, Pencovich N, Shussman N, Wasserberg N, Reshef A, Quint E, Lishtzinsky YY, Kashtan H, Shabtai M, Brenner B, Sharon E, Allweis T, Shahar N, Eckerling A, Sandbank E, Zmora O, Ben-Eliyahu S. PMID: 42088573 [PubMed]
	Nanomaterials reshaping cancer radiotherapy: Radiosensitization mechanisms, delivery and theranostic platforms, multimodal synergy, and clinical translation strategies. Mater Today Bio Liu J, Ding X, Li M, Pang H, Liu Z, Yang B. PMID: 42088562 [PubMed]
	Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1). Front Immunol Beas-Lozano EL, Scagliarini S, Valdez-Sandoval PI, Esparza-Orozco MF, Bilen MA, Bamias A, Li H, Juan Fita MJ, Kopecky J, Manneh Kopp R, Ghosn M, Fay AP, Bhuva D, Kucharz J, Büttner T, Molina-Cerrillo J, Fiala O, Rizzo A, Maiorano BA, Soares A, Buti S, Marques Monteiro FS, Massari F, Santoni M, Bourlon MT. PMID: 42088516 [PubMed - indexed for MEDLINE]
	The application and challenges of immune checkpoint inhibitors in lung cancer therapy. Front Immunol Li B, Ren Y, Zhang X. PMID: 42088497 [PubMed - indexed for MEDLINE]
	Advances in immunotherapy for renal cell carcinoma: a comprehensive review. Front Immunol Rajih E, Bakhsh A, Borhan WM, Alqahtani SAM. PMID: 42088496 [PubMed - indexed for MEDLINE]
	A Darwinian Perspective on Tumor Evolution. Int J Biol Sci Carnero A. PMID: 42088420 [PubMed - indexed for MEDLINE]
	Recent Advances in Novel Drug Delivery Systems for the Management of Cutaneous Squamous Cell Carcinoma. Int J Nanomedicine Fu X, Zhang Z, Dong Q, Li S, Wang X, Zhang H, Bai J, Han H, Shi L, Zheng K, Liang L. PMID: 42088400 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 1932221

Page 1 of 96612



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy